Investor Relations

Eton Pharmaceuticals, Inc. is a commercial company focused on developing, acquiring, and commercializing high-potential therapies for the treatment of patients with rare diseases. We have a diversified pipeline of product candidates across multiple therapeutic areas, and a team with significant expertise in bringing products from clinical trials to patients with exceptional speed.

Volume :

Minimum 15 minutes delayed. Source: LSEG

News Releases
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
July 29, 2026
FDA submission seeks to bring KHINDIVI to larger pediatric patient population within the adrenal insufficiency market New formulation successfully demonstrated bioequivalence to ALKINDI SPRINKLE ® Submission allows for a potential first half 2027 approval of the expanded indication DEER PARK, Ill.,
Read More
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
May 19, 2026
IMPAVIDO ® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania species Leishmaniasis is a rare but potentially life-threatening parasitic disease that can cause severe skin lesions or systemic infection involving internal
Read More
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
May 14, 2026
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million Q1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted
Read More
Email Alerts
Eton Latest Events
More events are coming soon.